Quote:
Originally Posted by pip08456
Incorrect name? Seems like the FT has never heard of a typo. Regeron instead of Regeneron. Does make the memo look rushed though.
|
The FT said there were actually two errors in the memo:
b) An incorrect name was used for the drug itself. The memo of 3rd October refers to it as a polyclonal antibody therapy whilst Regeneron's antibody therapy is monoclonal. Not an expert on the differences here eg if a cocktail is used, does it become "poly"?
b) Manufacturer's name, using the name Regeron instead of Regeneron. (Regeron focuses on reverse-aging biotechnology, especially on manufacturing human polypeptide growth factors for cosmetic applications including hair care).
A potential typo or genuine confusion with the other company.